Accueil・Liste d'Actions・Merck & Co Inc.

Merck & Co Inc.

Ouvert

SecteurSoins de santé

127.89 0.42

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

125.21

Max

129.94

Chiffres clés
By Trading Economics
Revenu	-7.2B -4.2B
Ventes	-114M 16B
P/E Moyenne du Secteur	36.834 64.641
BPA	-1.28
Rendement du dividende	2.5
Marge bénéficiaire	-26.053
Employés	73,000
EBITDA	-6.4B -2B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+7.18% upside

Dividendes
By Acuity
Rendement du dividende Moyenne du Secteur	2.50% 2.31%
Prochains Résultats	4 août 2026
Date du Prochain Dividende	7 oct. 2026
Date du Prochain Détachement de Dividende	15 sept. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	35B 307B
Ouverture précédente	127.47
Clôture précédente	127.89

Sentiment de l'Actualité

By Acuity

21%

79%

48 / 340 Classement par Healthcare

Merck & Co Inc. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 août 2026, 20:03 UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 juil. 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 juil. 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 juil. 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 juil. 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 juil. 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24 juil. 2026, 18:56 UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22 juil. 2026, 19:46 UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21 juil. 2026, 19:56 UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20 juil. 2026, 20:02 UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Comparaison

Variation de prix

Merck & Co Inc. prévision

Objectif de Prix

By TipRanks

7.18% hausse

Prévisions sur 12 Mois

Moyen 136.94 USD 7.18%

Haut 155 USD

Bas 100 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

18 ratings

Achat

Maintien

Vente

Basé sur 18 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

48 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.